

**Blenrep (belantumab mafodotin-blmf)  
Effective 04/01/2021**

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization
<b>Benefit</b>	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

**Overview**

Multiple myeloma is a cancer of plasma cells. Malignant plasma cells accumulate in the bone marrow crowding out normal plasma cells used to help fight infection.

Blenrep (belantumab mafodotin-blmf) is an antibody-drug conjugate that mediates killing of tumor cells through MMAF-induced apoptosis, as well as by tumor cell lysis through antibody-dependent cellular toxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

**Coverage Guidelines**

Authorization may be reviewed for members new to AllWays Health Partners who are currently receiving treatment with Blenrep excluding when the product is obtained as samples or via manufacturer’s patient assistance programs

**OR**

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

1. The member has a diagnosis of relapsed or refractory multiple myeloma
2. The member has received at least 4 prior therapies including at least one drug from each of the following categories:
  - a. Anti-CD38 monoclonal antibody (e.g. daratumumab)
  - b. Proteasome inhibitor (e.g. bortezomib, ixazomib, carfilzomib)
  - c. Immunomodulatory agent (e.g. lenalidomide pomalidomide)

**Continuation of Therapy**

Reauthorization may be granted when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.



### **Limitations**

Initial approvals and reauthorizations will be for 12 months.

### **References**

1. Blenrep (belantamab mafodotin) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2020.
2. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/761158s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf)

### **Review History**

3/17/2021 – Created and Reviewed at March P&T. Effective 4/1/21.

### **Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.